Join the Diabetic Retinopathy group to help and get support from people like you.
Diabetic Retinopathy News
ENDO: AI Model Integrated Into Retina Tracker IDs Diabetic Retinopathy
FRIDAY, July 18, 2025 – An artificial intelligence (AI) model integrated into a retina tracker for diabetic retinopathy can achieve high accuracy while being resource-efficient, according to a study...
AI Can Help Screen For Vision-Destroying Diabetic Eye Disease
WEDNESDAY, July 16, 2025 — A new AI-powered retina tracker can help doctors screen for a vision-destroying diabetic eye disease, researchers say. The Simple Mobile AI Retina Tracker (SMART) program a...
Prevalence, Incidence of Diabetic Retinal Disease Increased in Recent Years
TUESDAY, July 8, 2025 – The prevalence and incidence of diabetic retinal disease (DRD) has increased in recent years, while the incidence of vision-threatening diabetic retinopathy (VTDR), diabetic...
HIV Drug, Lamivudine, Potentially Effective Against Diabetic Eye Disease
FRIDAY, June 20, 2025 — A cheap HIV drug might be able to help people with diabetes reverse a complication that can lead to blindness, a new small-scale study says. The drug, lamivudine, appears to i...
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
South San Francisco, CA – May 22, 2025 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo...
Intraocular Inflammation More Common With Aflibercept Injections in Real-World Setting
FRIDAY, May 9, 2025 – The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of aflibercept than in clinical trials, according to...
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
TUESDAY, Dec. 17, 2024 – Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase 4 inhibitor (DPP4i),...
Diabetes Can Damage Your Eyes' Retinas: An Expert Explains
TUESDAY, Nov. 5, 2024 – People with diabetes face a number of health challenges related to their chronic condition, and loss of vision due to retinal damage is one of them. “Diabetes can silently d...
Social Determinants of Health Affect Monitoring for Diabetic Retinopathy
MONDAY, Sept. 16, 2024 – Certain social determinants of health (SDOH) affect monitoring for diabetic retinopathy (DR), according to a study published online Sept. 12 in JAMA Ophthalmology. Azraa S....
GLP1RAs Tied to Greater Risk of Diabetic Retinopathy Progression Than SGLT2is
FRIDAY, July 26, 2024 – In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with increased risks of...
FDA Approves Yesafili (aflibercept-jbvf), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
FDA Approves Opuviz (aflibercept-yszy), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Opuviz (aflibercept-yszy), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
FDA Approves Eylea HD (aflibercept) Injection 8 mg for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea HD (aflibercept)...
FDA Approves Cimerli (ranibizumab-eqrn), an Interchangeable Biosimilar to Lucentis
REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy
TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all...